RATIONALE: Salvinorin A is the active component of the hallucinogenic plant Salvia divinorum. The potential mode of action of this hallucinogen was unknown until recently. A recent in vitro study detected high affinity and efficacy of salvinorin A at kappa-opioid receptors. It was postulated that salvinorin A would produce discriminative stimulus effects similar to those of a high efficacy kappa-agonist (U69,593) in rhesus monkeys. METHODS: Monkeys were previously trained to discriminate U69,593 (0.0056 or 0.013 mg/kg; s.c.) from vehicle in a food-reinforced FR20 (fixed ratio 20) operant conditioning procedure (n=3). The ability of salvinorin A to cause generalization (> or =90% U69,593-appropriate responding) was examined in time course and cumulative dose-effect curve studies. RESULTS: All subjects dose-dependently emitted full U69,593-appropriate responding after salvinorin A (0.001-0.032 mg/kg, SC). Salvinorin A-induced generalization started 5-15 min after injection, and dissipated by 120 min. The opioid antagonist quadazocine (0.32 mg/kg) fully blocked the effects of salvinorin A. The kappa-selective antagonist GNTI (1 mg/kg; 24 h pretreatment) did not cause significant antagonism of the effects of salvinorin A (GNTI, under these conditions, was only effective as an antagonist in two of three monkeys). The NMDA antagonist ketamine (0.1-3.2 mg/kg) was not generalized by any subject, indicating that not all compounds that produce hallucinogenic or psychotomimetic effects in humans are generalized by subjects trained to discriminate U69,593. CONCLUSIONS: The naturally occurring hallucinogen salvinorin A produces discriminative stimulus effects similar to those of a high efficacy kappa-agonist in non-human primates.
RATIONALE: Salvinorin A is the active component of the hallucinogenic plant Salvia divinorum. The potential mode of action of this hallucinogen was unknown until recently. A recent in vitro study detected high affinity and efficacy of salvinorin A at kappa-opioid receptors. It was postulated that salvinorin A would produce discriminative stimulus effects similar to those of a high efficacy kappa-agonist (U69,593) in rhesus monkeys. METHODS: Monkeys were previously trained to discriminate U69,593 (0.0056 or 0.013 mg/kg; s.c.) from vehicle in a food-reinforced FR20 (fixed ratio 20) operant conditioning procedure (n=3). The ability of salvinorin A to cause generalization (> or =90% U69,593-appropriate responding) was examined in time course and cumulative dose-effect curve studies. RESULTS: All subjects dose-dependently emitted full U69,593-appropriate responding after salvinorin A (0.001-0.032 mg/kg, SC). Salvinorin A-induced generalization started 5-15 min after injection, and dissipated by 120 min. The opioid antagonist quadazocine (0.32 mg/kg) fully blocked the effects of salvinorin A. The kappa-selective antagonist GNTI (1 mg/kg; 24 h pretreatment) did not cause significant antagonism of the effects of salvinorin A (GNTI, under these conditions, was only effective as an antagonist in two of three monkeys). The NMDA antagonist ketamine (0.1-3.2 mg/kg) was not generalized by any subject, indicating that not all compounds that produce hallucinogenic or psychotomimetic effects in humans are generalized by subjects trained to discriminate U69,593. CONCLUSIONS: The naturally occurring hallucinogen salvinorin A produces discriminative stimulus effects similar to those of a high efficacy kappa-agonist in non-human primates.
Authors: S Stevens Negus; Nancy K Mello; David C Linsenmayer; R M Jones; Philip S Portoghese Journal: Psychopharmacology (Berl) Date: 2002-03-13 Impact factor: 4.530
Authors: J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney Journal: Arch Gen Psychiatry Date: 1994-03
Authors: Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington Journal: Eur J Pharm Biopharm Date: 2009-06 Impact factor: 5.571
Authors: Michael J Caspers; Todd D Williams; Kimberly M Lovell; Anthony Lozama; Eduardo R Butelman; Mary Jeanne Kreek; Matthew Johnson; Roland Griffiths; Katherine Maclean; Thomas E Prisinzano Journal: Anal Methods Date: 2013-12-21 Impact factor: 2.896
Authors: Cécile Béguin; Katharine K Duncan; Thomas A Munro; Douglas M Ho; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen Journal: Bioorg Med Chem Date: 2008-12-14 Impact factor: 3.641
Authors: Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek Journal: Psychopharmacology (Berl) Date: 2010-01-19 Impact factor: 4.530
Authors: Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano Journal: J Med Chem Date: 2008-04-02 Impact factor: 7.446